Trichinella spiralis Infection Inhibits the Efficacy of RBD Protein of SARS-CoV-2 Vaccination via Regulating Humoral and Cellular Immunity

Author:

Zhu Feifan1,Zheng Wenwen1,Gong Yiyan1,Zhang Jinyuan1,Yu Yihan2,Zhang Jixian2,Liu Mengjun2,Guan Fei1ORCID,Lei Jiahui1ORCID

Affiliation:

1. Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China

2. Department of Pulmonary Medicine, Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan 430015, China

Abstract

Vaccines are the most effective and feasible way to control pathogen infection. Helminths have been reported to jeopardize the protective immunity mounted by several vaccines. However, there are no experimental data about the effect of helminth infection on the effectiveness of COVID-19 vaccines. Here, a mouse model of trichinosis, a common zoonotic disease worldwide, was used to investigate effects of Trichinella spiralis infection on the RBD protein vaccine of SARS-CoV-2 and the related immunological mechanism, as well as the impact of albendazole (ALB) deworming on the inhibitory effect of the parasite on the vaccination. The results indicated that both the enteric and muscular stages of T. spiralis infection inhibited the vaccine efficacy, evidenced by decreased levels of IgG, IgM, sIgA, and reduced serum neutralizing antibodies, along with suppressed splenic germinal center (GC) B cells in the vaccinated mice. Pre-exposure to trichinosis promoted Th2 and/or Treg immune responses in the immunized mice. Furthermore, ALB treatment could partially reverse the inhibitory effect of T. spiralis infection on the efficiency of the vaccination, accompanied by a restored proportion of splenic GC B cells. Therefore, given the widespread prevalence of helminth infections worldwide, deworming therapy needs to be considered when implementing COVID-19 vaccination strategies.

Funder

Nature Science Foundation of Hubei Province

Publisher

MDPI AG

Reference60 articles.

1. WHO (2024, May 25). Coronavirus Disease (COVID-19). Available online: https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19).

2. Evidence of the efficacy and the effectiveness of first generation COVID-19 vaccines in clinical trials and real-world studies;Li;Zoonoses,2022

3. COVID-19 vaccine development: Milestones, lessons and prospects;Li;Signal Transduct. Target. Ther.,2022

4. Cabral-Marques, and N. Rezaei. COVID-19 vaccinations: The unknowns, challenges, and hopes;Mohamed;J. Med. Virol.,2022

5. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity;Yang;Nature,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3